MARKET

HCM

HCM

Hutchmed (China) Limited
NASDAQ
16.80
-0.05
-0.30%
After Hours: 16.10 -0.7 -4.17% 16:17 03/28 EDT
OPEN
16.93
PREV CLOSE
16.85
HIGH
17.05
LOW
16.69
VOLUME
62.06K
TURNOVER
0
52 WEEK HIGH
20.73
52 WEEK LOW
10.68
MARKET CAP
2.93B
P/E (TTM)
28.98
1D
5D
1M
3M
1Y
5Y
HUTCHMED’s Savolitinib sNDA Under Review in China
TipRanks · 21h ago
On Wednesday, HUTCHMED Announced Savolitinib sNDA Accepted in China For Treatment-Naïve Or Previously Treated Patients With Locally Advanced Or Metastatic MET Exon 14 NSCLC
The supplemental New Drug Application for savolitinib has been accepted for review by the China National Medical Products Administration. If approved, the label indication for the drug will be expanded to include treatment-naïve patients in China. The drug is being developed for patients with lung cancer.
Benzinga · 23h ago
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
Barchart · 1d ago
Weekly Report: what happened at HCM last week (0318-0322)?
Weekly Report · 3d ago
HUTCHMED Advances Sovleplenib Trial in China
TipRanks · 6d ago
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
HUTCHMED (China) Limited has initiated the registration stage of the Phase II/III clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia in China. The company is a subsidiary of HUTCH MEDIA.
Barchart · 03/21 19:00
Hutchmed Is Turning Profitable
Hutchmed (China) Limited is a biopharmaceutical company with a market capitalization of $3 billion. The company's total revenue doubled to $838 million in 2023, driven by sales of the cancer drug FRUZAQLA. HCM delivered a profit of $100.8 million and has a strong cash position of over $880 million. In December, Tudor Invest Holdings upgraded HCM from a Hold to a Buy on expectations of the company turning profitable.
Seeking Alpha · 03/20 12:55
Weekly Report: what happened at HCM last week (0311-0315)?
Weekly Report · 03/18 09:29
More
About HCM
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Webull offers HUTCHMED (China) Ltd (ADR) stock information, including NASDAQ: HCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HCM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HCM stock methods without spending real money on the virtual paper trading platform.